For example, the KEYNOTE trials of pembrolizumab (Clinical- trials.gov: NCT01295827 and NCT01905657) scored patients for immune checkpoint expression by the presence of the PD-L1 protein on the surface of tumor cells (TC). The gene discussed is CD274; the disease is neoplasm.